The fact that Celastrol targets AR-ERG-NF-κB signaling and inhibits human VCaP PCa tumor growth in vivo provides strong support for the proof-of-concept of using Celastrol for T/E fusion expressing PCa, which may benefit more than half of PCa patients who carry T/E fusions in their tumors. The gene discussed is NFKB1; the disease is neoplasm.